Michael Frumer1, Nadav Milk2, Gal Rinott Mizrahi3, Sergiu Bistritzky4, Itay Sternberg5,2, Ilan Leibovitch5,2, Yoram Dekel3,6, Gilad E Amiel4,6, Amnon Zisman5,7, Jack Baniel8,5, Miki Haifler5,7, Jonathan Gal7, Azik Hoffman4,6, Itay Sagy5,2,3, Barak Rosenzweig5,9, Rennen Haramaty9, Shay Golan8,5. 1. Section of Urology, Rabin Medical Center, Jabotinsky St 39, 4941492, Petah Tikva, Israel. Mic1039@gmail.com. 2. Meir Medical Center, Kfar Saba, Israel. 3. Carmel Medical Center, Haifa, Israel. 4. Rambam Health Care Campus, Haifa, Israel. 5. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 6. Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel. 7. Shamir Medical Center, Tzrifin, Israel. 8. Section of Urology, Rabin Medical Center, Jabotinsky St 39, 4941492, Petah Tikva, Israel. 9. Chaim Sheba Medical Center, Ramat Gan, Israel.
Abstract
OBJECTIVES: To compare the ability of 68Ga -PSMA PET/CT (PSMA PET/CT) and multiparametric MRI (mpMRI) to exclude lymph node invasion (LNI) in patients who undergo radical prostatectomy (RP). MATERIALS AND METHODS: A multicenter cohort of patients who underwent PSMA PET/CT and pelvic mpMRI prior to RP with pelvic lymph node dissection (PLND) was analyzed. Increased Ga68-PSMA uptake on PET/CT and enlarged (> 10 mm) or abnormal lymph nodes on mpMRI were considered positive findings. The final surgical pathology served as the standard of reference. The negative predictive value (NPV) was calculated for each modality separately, as well as the combined value. RESULTS: Included were 89 patients with D'Amico intermediate (45%) or high-risk (55%) prostate cancer. The median number of extracted LN was 9 (IQR 6-14). LNI was found in 12 (13.5%) patients. The NPV of mpMRI, PSMA PET/CT, and the two tests combined were 87%, 89%, and 90%, in the entire cohort, 95%, 97%, and 97% in patients with intermediate-risk disease, and 80%, 82%, and 83% in patients with high-risk disease, respectively. The median diameter of LN missed by both imaging and the median intranodal tumor diameter was 5.5 (IQR 3-10) mm and 1 (IQR 1-3) mm, respectively. CONCLUSIONS: PSMA PET/CT and mpMRI demonstrated similar performance in excluding pelvic LNI with NPV of approximately 90%. The combination of both tests does not improve NPV significantly. Therefore, even in the era of advanced imaging, PLND is still recommended for accurate staging, especially in the high-risk population.
OBJECTIVES: To compare the ability of 68Ga -PSMA PET/CT (PSMA PET/CT) and multiparametric MRI (mpMRI) to exclude lymph node invasion (LNI) in patients who undergo radical prostatectomy (RP). MATERIALS AND METHODS: A multicenter cohort of patients who underwent PSMA PET/CT and pelvic mpMRI prior to RP with pelvic lymph node dissection (PLND) was analyzed. Increased Ga68-PSMA uptake on PET/CT and enlarged (> 10 mm) or abnormal lymph nodes on mpMRI were considered positive findings. The final surgical pathology served as the standard of reference. The negative predictive value (NPV) was calculated for each modality separately, as well as the combined value. RESULTS: Included were 89 patients with D'Amico intermediate (45%) or high-risk (55%) prostate cancer. The median number of extracted LN was 9 (IQR 6-14). LNI was found in 12 (13.5%) patients. The NPV of mpMRI, PSMA PET/CT, and the two tests combined were 87%, 89%, and 90%, in the entire cohort, 95%, 97%, and 97% in patients with intermediate-risk disease, and 80%, 82%, and 83% in patients with high-risk disease, respectively. The median diameter of LN missed by both imaging and the median intranodal tumor diameter was 5.5 (IQR 3-10) mm and 1 (IQR 1-3) mm, respectively. CONCLUSIONS:PSMA PET/CT and mpMRI demonstrated similar performance in excluding pelvic LNI with NPV of approximately 90%. The combination of both tests does not improve NPV significantly. Therefore, even in the era of advanced imaging, PLND is still recommended for accurate staging, especially in the high-risk population.
Authors: Karim A Touijer; Robert Jeffery Karnes; Niccolo Passoni; Daniel D Sjoberg; Melissa Assel; Nicola Fossati; Giorgio Gandaglia; James A Eastham; Peter T Scardino; Andrew Vickers; Cesare Cozzarini; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2017-10-16 Impact factor: 20.096
Authors: Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin Journal: Urology Date: 2007-06 Impact factor: 2.649
Authors: Pim J van Leeuwen; Louise Emmett; Bao Ho; Warick Delprado; Francis Ting; Quoc Nguyen; Phillip D Stricker Journal: BJU Int Date: 2016-06-18 Impact factor: 5.588
Authors: Annika Herlemann; Vera Wenter; Alexander Kretschmer; Kolja M Thierfelder; Peter Bartenstein; Claudius Faber; Franz-Josef Gildehaus; Christian G Stief; Christian Gratzke; Wolfgang P Fendler Journal: Eur Urol Date: 2016-01-19 Impact factor: 20.096
Authors: A M Hövels; R A M Heesakkers; E M Adang; G J Jager; S Strum; Y L Hoogeveen; J L Severens; J O Barentsz Journal: Clin Radiol Date: 2008-02-04 Impact factor: 2.350
Authors: Sui Wai Ling; Anouk C de Jong; Ivo G Schoots; Kazem Nasserinejad; Martijn B Busstra; Astrid A M van der Veldt; Tessa Brabander Journal: Eur Urol Open Sci Date: 2021-09-28